IBDEI37D ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,51137,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51137,1,3,0)
 ;;=3^Gout,Unspec
 ;;^UTILITY(U,$J,358.3,51137,1,4,0)
 ;;=4^M10.9
 ;;^UTILITY(U,$J,358.3,51137,2)
 ;;=^5010404
 ;;^UTILITY(U,$J,358.3,51138,0)
 ;;=G90.59^^193^2503^35
 ;;^UTILITY(U,$J,358.3,51138,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51138,1,3,0)
 ;;=3^Complex Regional Pain Syndrome I,Unspec
 ;;^UTILITY(U,$J,358.3,51138,1,4,0)
 ;;=4^G90.59
 ;;^UTILITY(U,$J,358.3,51138,2)
 ;;=^5004171
 ;;^UTILITY(U,$J,358.3,51139,0)
 ;;=G56.01^^193^2503^13
 ;;^UTILITY(U,$J,358.3,51139,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51139,1,3,0)
 ;;=3^Carpal Tunnel Syndrome,Right Upper Limb
 ;;^UTILITY(U,$J,358.3,51139,1,4,0)
 ;;=4^G56.01
 ;;^UTILITY(U,$J,358.3,51139,2)
 ;;=^5004018
 ;;^UTILITY(U,$J,358.3,51140,0)
 ;;=G56.02^^193^2503^12
 ;;^UTILITY(U,$J,358.3,51140,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51140,1,3,0)
 ;;=3^Carpal Tunnel Syndrome,Left Upper Limb
 ;;^UTILITY(U,$J,358.3,51140,1,4,0)
 ;;=4^G56.02
 ;;^UTILITY(U,$J,358.3,51140,2)
 ;;=^5004019
 ;;^UTILITY(U,$J,358.3,51141,0)
 ;;=G56.21^^193^2503^60
 ;;^UTILITY(U,$J,358.3,51141,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51141,1,3,0)
 ;;=3^Lesion of Ulnar Nerve,Right Upper Limb
 ;;^UTILITY(U,$J,358.3,51141,1,4,0)
 ;;=4^G56.21
 ;;^UTILITY(U,$J,358.3,51141,2)
 ;;=^5004024
 ;;^UTILITY(U,$J,358.3,51142,0)
 ;;=G56.22^^193^2503^59
 ;;^UTILITY(U,$J,358.3,51142,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51142,1,3,0)
 ;;=3^Lesion of Ulnar Nerve,Left Upper Limb
 ;;^UTILITY(U,$J,358.3,51142,1,4,0)
 ;;=4^G56.22
 ;;^UTILITY(U,$J,358.3,51142,2)
 ;;=^5004025
 ;;^UTILITY(U,$J,358.3,51143,0)
 ;;=L40.52^^193^2503^143
 ;;^UTILITY(U,$J,358.3,51143,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51143,1,3,0)
 ;;=3^Psoriatic Arthritis Mutilans
 ;;^UTILITY(U,$J,358.3,51143,1,4,0)
 ;;=4^L40.52
 ;;^UTILITY(U,$J,358.3,51143,2)
 ;;=^5009167
 ;;^UTILITY(U,$J,358.3,51144,0)
 ;;=L40.53^^193^2503^144
 ;;^UTILITY(U,$J,358.3,51144,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51144,1,3,0)
 ;;=3^Psoriatic Spondylitis
 ;;^UTILITY(U,$J,358.3,51144,1,4,0)
 ;;=4^L40.53
 ;;^UTILITY(U,$J,358.3,51144,2)
 ;;=^5009168
 ;;^UTILITY(U,$J,358.3,51145,0)
 ;;=M32.9^^193^2503^187
 ;;^UTILITY(U,$J,358.3,51145,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51145,1,3,0)
 ;;=3^Systemic Lupus Erythematosus,Unspec
 ;;^UTILITY(U,$J,358.3,51145,1,4,0)
 ;;=4^M32.9
 ;;^UTILITY(U,$J,358.3,51145,2)
 ;;=^5011761
 ;;^UTILITY(U,$J,358.3,51146,0)
 ;;=M32.0^^193^2503^183
 ;;^UTILITY(U,$J,358.3,51146,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51146,1,3,0)
 ;;=3^Systemic Lupus Erythematosus,Drug-Induced
 ;;^UTILITY(U,$J,358.3,51146,1,4,0)
 ;;=4^M32.0
 ;;^UTILITY(U,$J,358.3,51146,2)
 ;;=^5011752
 ;;^UTILITY(U,$J,358.3,51147,0)
 ;;=M32.13^^193^2503^185
 ;;^UTILITY(U,$J,358.3,51147,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51147,1,3,0)
 ;;=3^Systemic Lupus Erythematosus,Lung Involvement
 ;;^UTILITY(U,$J,358.3,51147,1,4,0)
 ;;=4^M32.13
 ;;^UTILITY(U,$J,358.3,51147,2)
 ;;=^5011756
 ;;^UTILITY(U,$J,358.3,51148,0)
 ;;=M32.14^^193^2503^184
 ;;^UTILITY(U,$J,358.3,51148,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51148,1,3,0)
 ;;=3^Systemic Lupus Erythematosus,Glomerular Disease
 ;;^UTILITY(U,$J,358.3,51148,1,4,0)
 ;;=4^M32.14
 ;;^UTILITY(U,$J,358.3,51148,2)
 ;;=^5011757
 ;;^UTILITY(U,$J,358.3,51149,0)
 ;;=M32.12^^193^2503^186
 ;;^UTILITY(U,$J,358.3,51149,1,0)
 ;;=^358.31IA^4^2
